Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors

(2018) Anish Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

The ATR Inhibitor AZD6738 Synergizes with GemcitabineIn VitroandIn Vivoto Induce Pancreatic Ductal Adenocarcinoma Regression

(2018) Yann Wallez et al.   MOLECULAR CANCER THERAPEUTICS

ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells

(2018) Dongsung Kim et al.   NUCLEIC ACIDS RESEARCH

ATR/CHK1 inhibitors and cancer therapy

(2018) Zhaojun Qiu et al.   RADIOTHERAPY AND ONCOLOGY

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

(2018) Juan Jin et al.   NEOPLASIA

VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes.

(2018) Andrew Tutt et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors.

(2018) Geraldine Helen O'Sullivan Coyne et al.   JOURNAL OF CLINICAL ONCOLOGY

An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).

(2018) John Heymach et al.   JOURNAL OF CLINICAL ONCOLOGY

Correction to: Emerging roles of Myc in stem cell biology and novel tumor therapies

(2018) Go J. Yoshida   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The essential kinase ATR: ensuring faithful duplication of a challenging genome

(2017) Joshua C. Saldivar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Clinical correlation of extensive-stage small-cell lung cancer genomics

(2016) A. Dowlati et al.   ANNALS OF ONCOLOGY

Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

(2016) T.A. Yap et al.   EUROPEAN JOURNAL OF CANCER

Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells

(2016) Hee-Jun Kim et al.   INTERNATIONAL JOURNAL OF CANCER

Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation

(2016) Edyta Biskup et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei

(2016) Magnus T. Dillon et al.   MOLECULAR CANCER THERAPEUTICS

ATR inhibition rewires cellular signaling networks induced by replication stress

(2016) Sebastian A. Wagner et al.   PROTEOMICS

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells

(2015) M. Kwok et al.   BLOOD

Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity

(2015) Timothy A. Yap et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

(2015) Frank P. Vendetti et al.   Oncotarget

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

(2015) Amy B. Hall et al.   Oncotarget

Strain Background Determines Lymphoma Incidence in Atm Knockout Mice

(2015) Paula C. Genik et al.   NEOPLASIA

Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents

(2014) Yuxia Cui et al.   CELL CYCLE

ATR inhibition preferentially targets homologous recombination-deficient tumor cells

(2014) M Krajewska et al.   ONCOGENE

CHK2 kinase in the DNA damage response and beyond

(2014) L. Zannini et al.   Journal of Molecular Cell Biology

ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status

(2013) C. J. Huntoon et al.   CANCER RESEARCH

Targeting ATR in DNA damage response and cancer therapeutics

(2013) Emmanouil Fokas et al.   CANCER TREATMENT REVIEWS

Causes and consequences of replication stress

(2013) Michelle K. Zeman et al.   NATURE CELL BIOLOGY

Mechanisms of resistance to therapies targeting BRCA-mutant cancers

(2013) Christopher J Lord et al.   NATURE MEDICINE

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation

(2012) E Fokas et al.   Cell Death & Disease

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

(2011) Philip M Reaper et al.   Nature Chemical Biology

New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

(2010) Y. Dai et al.   CLINICAL CANCER RESEARCH

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

(2010) Cynthia X. Ma et al.   TRENDS IN MOLECULAR MEDICINE

Death through a tragedy: mitotic catastrophe

(2008) H Vakifahmetoglu et al.   CELL DEATH AND DIFFERENTIATION

The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage

(2008) E M Bahassi et al.   ONCOGENE